Olutasidenib
Rezlidhi · IDH1 inhibitor
Differentiation syndrome and tumor lysis in AML.
Tazverik · TAZ
EZH2 inhibitor · approved 2020 · 7 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
First-in-class EZH2 inhibitor with a generally low direct renal toxicity — the kidney-relevant concern is treatment-related tumor lysis in lymphoma.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Tazemetostat is generally well tolerated with low direct organ toxicity; the noted boxed risk is secondary T-cell lymphoma/myeloid malignancy. Tumor lysis is an uncommon, treatment-related concern in responding lymphoma. A discrete AKI rate is not quantified and direct nephrotoxicity is low. Reported rate: grade >=3 hyponatremia in 7% — 74 patients with relapsed or refractory malignant pleural mesothelioma (99% BAP1-inactivated) receiving single-agent… (Zauderer 2022, PMID 35588752).Source: Zauderer et al., Lancet Oncol 2022
Tumor lysis, if it occurs, is early after response; prerenal effects track GI toxicity.
Distilled from: “Tumor lysis, if it occurs, is early after response; prerenal effects track intercurrent GI toxicity.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative grade ≥3 incidence
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Oral selective inhibitor of EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates histone H3 lysine 27 (H3K27me3). Inhibition reverses aberrant gene silencing in EZH2-mutant follicular lymphoma and in INI1/SMARCB1-deficient epithelioid sarcoma.
7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
No dose adjustment of TAZVERIK is recommended for patients with mild to severe renal impairment or end stage renal disease [see Clinical Pharmacology ( 12.3 )] .
Kidney rows of the label's dosage tables
From the TAZVERIK label (Apr 2026) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 1,622 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
216 of 1,622 reports
Reported with hospitalization
324 of 1,622 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Tazemetostat sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Rezlidhi · IDH1 inhibitor
Differentiation syndrome and tumor lysis in AML.
Monjuvi · Anti-CD19 antibody
Tumor lysis and infusion reactions in lymphoma.
Poteligeo · Anti-CCR4 antibody
Tumor lysis and rare AKI; cutaneous T-cell lymphoma.
Rydapt · FLT3 / multikinase inhibitor
Tumor lysis, edema and QT in AML/mastocytosis.
Rytelo · Telomerase inhibitor
2024 MDS agent; tumor lysis risk.
Daurismo · Hedgehog (SMO) inhibitor
QT prolongation and muscle spasms; AML.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.